MIST

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: HRTX KROS FENC MDWD NKTX OBIO RNAC SLGL ARCT VYGR

| Held by: SURI GWX

Scroll to Statements

Index	-
Market Cap	159.36M
Enterprise Value	112.47M
Income	-68.36M
Sales	1.78M
Book/sh	0.31
Cash/sh	1.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	38
IPO	May 09, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	89.53
P/B	4.18
P/C	0.87
P/FCF	-
EV/EBITDA	-
EV/Sales	63.19
Quick Ratio	9.09
Current Ratio	9.18
Debt/Eq	3.81
LT Debt/Eq	3.79
Option/Short	Yes / Yes

EPS (ttm)	-0.68
EPS next Y	-1.02
EPS next Q	-0.19
EPS this Y	-24.00%
EPS next Y	-9.86%
EPS next 5Y	17.74%
EPS past 3/5Y	18.24% 15.09%
Sales past 3/5Y	-32.38% -
EPS Y/Y TTM	17.64%
Sales Y/Y TTM	-
EPS Q/Q	36.11%
Sales Q/Q	-
Earnings	May 13 BMO
EPS/Sales Surpr.	-205.26% -99.21%

Insider Own	0.90%
Insider Trans	-29.97%
Inst Own	24.00%
Inst Trans	-1.67%
ROA	-53.49%
ROE	-456.88%
ROIC	-39.58%
Gross Margin	91.20%
Oper. Margin	-3679.43%
Profit Margin	-3832.01%
SMA20	-0.97%
SMA50	-11.93%
SMA200	-29.80%
Trades

Shs Outstand	124.50M
Shs Float	123.37M
Short Float	10.21%
Short Ratio	8.22
Short Interest	12.60M
52W High	3.06 -58.17%
52W Low	1.00 28.00%
Volatility	5.80% 5.77%
ATR (14)	0.08
RSI (14)	44.25
Beta	0.97
Rel Volume	0.30
Avg Volume	1.53M
Volume	454,118

Perf Week	-3.03%
Perf Month	5.79%
Perf Quarter	-36.32%
Perf Half Y	-40.47%
Perf YTD	-36.63%
Perf Year	-50.00%
Perf 3Y	-62.90%
Perf 5Y	-76.60%
Perf 10Y	-
Recom	1.33
Target Price	6.33
Prev Close	1.31
Price	1.28
Change	-2.29%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-26	Initiated	Raymond James	Strong Buy	$6
Dec-15-25	Upgrade	TD Cowen	Hold → Buy	$8
Sep-11-25	Initiated	Wells Fargo	Overweight	$4
Jun-05-25	Resumed	H.C. Wainwright	Buy	$5
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$9
Jun-20-23	Downgrade	Jefferies	Buy → Hold	$8 → $4
Apr-22-22	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $10
Mar-05-21	Initiated	H.C. Wainwright	Buy	$20
Jul-29-20	Upgrade	Oppenheimer	Perform → Outperform	$18
Jul-24-20	Upgrade	Jefferies	Hold → Buy
Mar-25-20	Downgrade	Jefferies	Buy → Hold	$28 → $3
Mar-24-20	Downgrade	Piper Sandler	Overweight → Neutral	$26.50 → $3
Mar-24-20	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-19	Initiated	Oppenheimer	Outperform	$32
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26.50
Jun-03-19	Initiated	Jefferies	Buy	$28
Jun-03-19	Initiated	Cowen	Outperform	$32

Show Previous Ratings

Jul-02-26 09:30PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-26 08:30AM	Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board (Business Wire)
May-14-26 08:30AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire) -5.23%
May-13-26 08:44PM	Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary (Moby) -9.47%
07:00PM	Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
09:34AM	Loading…
09:34AM	Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST) (InvestorsHub)
07:18AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
07:11AM	Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-26 08:00AM	Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026 (GlobeNewswire)
Apr-10-26 08:00AM	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients With PSVT (GlobeNewswire)
Apr-07-26 08:30AM	Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.92%
Apr-02-26 08:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.34%
Mar-31-26 08:00AM	Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies (GlobeNewswire) +17.82%
Mar-20-26 03:01PM	Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -20.00%
07:37AM	Milestone Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:12AM	Loading…
07:12AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT (GlobeNewswire)
Mar-16-26 08:13AM	Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session (GlobeNewswire)
Mar-12-26 08:00AM	Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 (GlobeNewswire)
Feb-26-26 08:00AM	Milestone Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-10-26 08:00AM	Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer (GlobeNewswire)
Feb-03-26 08:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-27-26 12:00PM	All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy (Zacks)
08:10AM	Milestone Pharmaceuticals announces U.S. availability of cardamyst (TipRanks)
Jan-26-26 08:00AM	Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) (GlobeNewswire)
Jan-07-26 08:22AM	Milestone announces acceptance of MAA by EMA for etripamil nasal spray (TipRanks)
Jan-06-26 08:00AM	Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency (GlobeNewswire)
Dec-17-25 05:00PM	Aptars Bidose Nasal System Delivers CARDAMYST (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) (Business Wire)
Dec-16-25 10:10AM	Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval (TipRanks) -6.18%
Dec-12-25 08:00PM	Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) (GlobeNewswire) -18.31%
Dec-02-25 05:21PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:16AM	Loading…
Nov-25-25 08:16AM	Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects (Insider Monkey)
Nov-12-25 07:01AM	Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Nov-04-25 04:05PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-25 08:00AM	Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 (GlobeNewswire)
Oct-09-25 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 (GlobeNewswire)
Aug-19-25 08:00AM	Milestone Pharmaceuticals to Present at Upcoming Conferences (GlobeNewswire)
Aug-12-25 02:02PM	Milestone Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) +7.10%
07:05AM	Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Jul-11-25 09:30AM	Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants (GlobeNewswire) -39.06%
06:01AM	Milestone Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
06:00AM	Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray (GlobeNewswire)
Jun-16-25 08:00AM	Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting (GlobeNewswire)
May-28-25 08:00AM	Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.04%
May-22-25 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why (Zacks)
May-14-25 07:22AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:04AM	Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Apr-09-25 10:26AM	Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT (Seeking Alpha) +10.78%
Apr-04-25 02:30PM	Stock Picks From Seeking Alpha's March 2025 New Analysts (Seeking Alpha) -7.24%
Apr-02-25 03:00PM	MIST Stock Falls 66% Following Complete Response Letter for Cardamyst (Zacks) +5.67%
08:37AM	Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen (TipRanks)
Apr-01-25 03:48PM	TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty (Investing.com) -5.01%
Mar-29-25 12:00PM	Milestone CRL affirms integrity of clinical data, says H.C. Wainwright (TipRanks)
Mar-28-25 07:00AM	FDA Issues Complete Response Letter for Etripamil for PSVT (GlobeNewswire) -60.89%
Mar-21-25 03:18PM	Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers (SeekingAlpha)
Mar-20-25 08:00AM	Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology (GlobeNewswire)
Mar-13-25 07:32AM	Milestone Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +5.18%
07:08AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Mar-04-25 08:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Milestone Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-19-25 08:00AM	Milestone Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil (GlobeNewswire)
Feb-11-25 08:00AM	Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 (GlobeNewswire)
Jan-28-25 08:00AM	Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC (GlobeNewswire)
Jan-07-25 08:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 08:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-19-24 09:55AM	After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright (Zacks)
Nov-12-24 09:17AM	Milestone Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
09:03AM	Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Sep-24-24 08:00AM	Milestone Pharmaceuticals to Host Investor KOL Event (GlobeNewswire)
Sep-06-24 07:00AM	Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China (GlobeNewswire)
Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire) +7.19%
Sep-03-24 08:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-26-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024 (GlobeNewswire)
Aug-08-24 04:41PM	Milestone Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) +6.02%
04:17PM	Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Jul-31-24 08:00AM	Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-12-24 08:00AM	Milestone Pharmaceuticals to Host KOL Event for Investors Learnings from the Field: Expert Perspectives on PSVT in the Community Setting on June 20, 2024 (GlobeNewswire)
May-31-24 08:00AM	Milestone Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST (GlobeNewswire) -5.45%
May-22-24 08:00AM	Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness (GlobeNewswire)
May-16-24 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know (Zacks)
May-13-24 01:53PM	MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:15AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:15AM	Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
May-02-24 08:00AM	Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 (GlobeNewswire)
Apr-17-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium (GlobeNewswire)
Apr-08-24 11:36AM	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Apr-01-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences (GlobeNewswire)
Mar-28-24 07:00AM	Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia (GlobeNewswire)
Mar-21-24 01:53PM	MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:14AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Feb-29-24 04:01PM	Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -21.13%
07:00AM	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-28-24 04:37PM	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-26-24 07:00AM	Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT (GlobeNewswire) +24.12%
Jan-18-24 01:23PM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Jan-16-24 09:35AM	Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround (Zacks)
Dec-27-23 11:11AM	Milestone Pharma (MIST) Down on Regulatory Update for Etripamil (Zacks) -5.53%
Dec-26-23 10:55AM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) -30.90%

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

CEOMr. Joseph G. Oliveto M.B.A.

CFO & Executive VP of Corporate DevelopmentMr. Amit Hasija

M.D.Dr. David B. Bharucha FACC

Ph.D.Dr. Philippe Douville M.B.A.

Chief Operating OfficerMr. Jeffrey Nelson

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oliveto Joseph	President and CEO	Apr 16 '26	Sale	2.26	36,500	82,490	446,244	Apr 20 04:06 PM
JOSEPH OLIVETO	Director	Apr 16 '26	Proposed Sale	2.20	36,500	80,300		Apr 16 04:12 PM
Bharucha David	Chief Medical Officer	Dec 15 '25	Sale	2.32	58,007	134,576	105,326	Jan 28 06:30 PM
Bharucha David	Chief Medical Officer	Jan 26 '26	Sale	1.93	12,245	23,633	113,181	Jan 28 06:30 PM
Nelson Jeffrey Edward	Chief Operating Officer	Dec 15 '25	Sale	2.32	58,007	134,576	41,993	Jan 28 06:30 PM
Nelson Jeffrey Edward	Chief Operating Officer	Jan 26 '26	Sale	1.93	12,245	23,633	49,848	Jan 28 06:30 PM
Muller Lorenz	Chief Commercial Officer	Dec 15 '25	Sale	2.32	53,566	124,273	196,486	Jan 28 06:30 PM
Muller Lorenz	Chief Commercial Officer	Jan 26 '26	Sale	1.93	11,180	21,577	205,406	Jan 28 06:30 PM
Hasija Amit	CFO & EVP of Corp. Development	Dec 15 '25	Sale	2.32	58,007	134,576	91,993	Jan 28 06:30 PM
Hasija Amit	CFO & EVP of Corp. Development	Jan 26 '26	Sale	1.93	12,245	23,633	99,848	Jan 28 06:30 PM
Oliveto Joseph	President and CEO	Dec 15 '25	Sale	2.32	133,054	308,685	450,667	Jan 28 06:30 PM
Oliveto Joseph	President and CEO	Jan 26 '26	Sale	1.93	34,523	66,629	482,744	Jan 28 06:30 PM
Oliveto Joseph	President and CEO	Jan 08 '26	Sale	2.25	43,000	96,750	303,721	Jan 09 04:53 PM
Oliveto Joseph	President and CEO	Jan 07 '26	Sale	2.25	500	1,125	346,721	Jan 09 04:53 PM
JOSEPH OLIVETO	Director	Jan 08 '26	Proposed Sale	2.15	79,500	170,925		Jan 08 04:25 PM
JOSEPH OLIVETO	Officer	Jan 07 '26	Proposed Sale	2.05	500	1,025		Jan 07 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Milestone Pharmaceuticals Inc

Upgrade your Finviz experience